Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMC303 in Advanced Solid Tumors
NCT03009214Phase 1Completed
- Sponsor
- amcure GmbH
- Start
- Dec 2016
- Primary completion
- Jul 2020
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of amc303 in solid tumor, sponsored by amcure GmbH. Primary endpoint: Safety and tolerability of AMC303 at 6 months. Started Dec 2016; status: completed.
02
Drugs
amc303
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03009214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009214.